查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1694921

2025年可逆性气道疾病治疗全球市场报告

Reversible Airway Diseases Treatment Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

可逆性呼吸道疾病治疗市场规模预计在未来几年将强劲成长。到 2029 年，这一数字将成长至 1,185 亿美元，复合年增长率为 6.8%。预测期内的成长是由于人口老化、慢性病盛行率增加、都市化和空气污染以及医疗保健覆盖率扩大。预测期内的主要趋势包括数位健康技术、新治疗方法的研究和开发、早期疗育和预防以及吸入器技术的进步。

预计未来几年慢性呼吸系统疾病的盛行率不断上升将推动可逆性呼吸道疾病治疗市场的成长。呼吸系统疾病是一种影响呼吸系统的疾病，包括肺、支气管、气管、喉、咽和鼻腔。慢性呼吸系统疾病的检测和治疗可以早期发现和诊断急性呼吸窘迫症候群等疾病，并透过降低併发症的风险来帮助防止病情恶化。例如，2024年2月，英国政府机构英国卫生安全局报告称，2023年至2022年，英格兰地区的结核病病例增加了10.7%，从4380例增加到4850例。这意味着结核病发病率在一年内大幅上升。因此，慢性呼吸系统疾病的增加预计将推动可逆性呼吸道疾病治疗市场的扩张。

预计医疗保健支出的增加将成为未来几年可逆性呼吸道疾病治疗市场成长的主要驱动力。医疗保健支出包括在特定医疗保健系统或经济体中在特定时期内分配给医疗保健服务和相关活动的全部财政资源。在治疗可逆性呼吸道疾病的背景下，增加医疗保健支出的趋势尤其重要，因为它推动了对研发、病患教育、获得先进药物和最尖端科技开发的投资增加。因此，增加医疗保健支出将有助于改善可逆性呼吸道疾病患者的管理和治疗效果。例如，截至2022年11月，加拿大卫生组织加拿大卫生资讯研究所（CIHI）的报告发现，加拿大的医疗保健费用在2021年达到3,280亿美元，然后在2022年增加到3,310亿美元。因此，医疗成本的上涨正在推动可逆性呼吸道疾病治疗市场的扩张。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、通膨、地缘政治、新冠疫情以及復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球可逆性气道疾病治疗PESTEL分析（政治、社会、技术、环境、法律、驱动因素、限制因素）
  • 最终用途产业分析
  • 全球可逆性气道疾病治疗市场：成长率分析
  • 全球可逆性气道疾病治疗市场表现：规模与成长，2019-2024
  • 全球可逆性气道疾病治疗市场预测：规模与成长，2024-2029 年，2034 年
  • 全球可逆性气道疾病治疗总目标市场（TAM）

第六章市场区隔

  • 全球可逆性气道疾病治疗市场（依治疗方法、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 胸部X光检查
  • 电脑断层扫描 (CT)
  • 肺部治疗
  • 外科移植
  • 製药
  • 全球可逆性气道疾病治疗市场（依疾病、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 气喘
  • 慢性支气管炎
  • 气肿
  • 囊肿纤维化
  • 细支气管炎
  • 其他疾病
  • 全球可逆性气道疾病治疗市场（依最终使用者、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 专科诊所
  • 其他最终用户
  • 全球可逆性气道疾病治疗市场胸部X光相片细分市场，依类型、绩效及预测，2019-2024年、2024-2029年、2034年
  • 标准胸部X光检查
  • 数位化胸部X光
  • 全球可逆性气道疾病治疗市场、电脑断层扫描 (CT) 扫描细分、按类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 高解析度电脑断层扫描
  • 螺旋电脑断层扫描
  • 全球可逆性气道疾病治疗市场肺部治疗细分市场，依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 吸入疗法
  • 肺康復
  • 氧气疗法
  • 全球可逆性气道疾病治疗市场，依手术、按植入物、按类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 肺移植
  • 支气管镜检查
  • 其他外科手术
  • 全球可逆性气道疾病治疗市场，依药物类型、绩效及预测细分，2019-2024 年、2024-2029 年、2034 年
  • 支气管扩张剂
  • 皮质类固醇
  • 抗胆碱药物
  • 其他药物

第七章 区域和国家分析

  • 全球可逆性气道疾病治疗市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球可逆性气道疾病治疗市场：按国家/地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 可逆性气道疾病治疗市场：竞争格局
  • 可逆性气道疾病治疗市场：公司简介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Sanofi SA
  • GlaxoSmithKline Plc
  • Medtronic plc
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Grifols SA
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dragerwerk AG & Co. KGaA
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年可逆性气道疾病治疗市场：提供新机会的国家
  • 2029年可逆性气道疾病治疗市场：细分市场带来新机会
  • 2029年可逆性气道疾病治疗市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r28898

Reversible airway diseases refer to conditions characterized by the temporary narrowing of airways, typically caused by inflammation and constriction of the surrounding smooth muscles. The primary objective of treating these conditions is to alleviate symptoms like cough and shortness of breath in order to enhance lung function.

The main categories of treatment options for reversible airway diseases include diagnostic procedures such as chest X-rays and computed tomography (CT) scans, therapeutic lung interventions, surgical procedures, organ transplants, and medications. A chest X-ray is a diagnostic imaging method that employs a small amount of ionizing radiation to produce images of the chest's internal structures, encompassing the heart, lungs, and bones. Various reversible airway diseases include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatment approaches are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

The reversible airway diseases treatment market research report is one of a series of new reports from The Business Research Company that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $85.53 billion in 2024 to $91.18 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to rising prevalence of reversible airway diseases, growing awareness of reversible airway diseases, increasing access to healthcare, rising disposable incomes.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $118.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to aging population, increasing prevalence of chronic diseases, rising urbanization and air pollution, expanding access to healthcare. Major trends in the forecast period include digital health technologies, research and development of new treatments, early intervention and prevention, inhaler technology advancements.

The increasing prevalence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market in the coming years. Respiratory diseases are conditions impacting the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Testing and treatment for chronic respiratory diseases enable early detection and diagnosis of conditions such as acute respiratory distress syndrome, helping to prevent progression by reducing the risk of complications. For example, in February 2024, the UK Health Security Agency, a government agency in the United Kingdom, reported a 10.7% increase in tuberculosis (TB) cases in England from 2022 to 2023, rising from 4,380 cases to 4,850. This represents a significant increase in TB incidence over the year. Consequently, the rise in chronic respiratory diseases is expected to fuel the expansion of the reversible airway disease treatment market.

The growing healthcare expenditure is poised to be a key driver of the reversible airway disease treatment market's growth in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services and associated activities within a specific healthcare system or economy over a defined period. The upward trend in healthcare spending is particularly significant in the context of treating reversible airway diseases, as it facilitates increased investments in research and development, patient education, access to advanced medications, and the development of cutting-edge technologies. Consequently, higher healthcare expenditures contribute to enhancing the management and treatment outcomes for individuals affected by reversible airway diseases. For example, as of November 2022, according to a report by the Canadian Institute for Health Information (CIHI), a Canada-based health organization, Canada's healthcare expenditure reached $328 billion in 2021 and subsequently increased to $331 billion in 2022. Thus, the escalating healthcare expenditures are propelling the expansion of the reversible airway disease treatment market.

Leading companies in the reversible airway disease treatment market are increasingly focusing on inhalational dosage forms in respiratory drug delivery to maintain their market position. For example, in May 2022, Alkem, a pharmaceutical company based in India, launched the Innohaler, a dry powder inhaler (DPI) device. This device is designed to improve life for patients with asthma and COPD by addressing significant gaps in asthma care within India. With the Innohaler, Alkem is stepping into the core inhalation therapeutics market, ensuring that each dose reaches the lungs efficiently. Furthermore, the device is supported by programs promoting patient awareness and adherence, maximizing its impact.

In October 2022, Lupin Ltd., an India-based pharmaceutical company, completed the purchase of two inhalation product brands from Sunovion Pharmaceuticals Inc. for $75 million. This strategic acquisition is set to fortify Lupin Ltd.'s inhalation product portfolio, with the addition of two brands, including Brovana (arformoterol tartrate) inhalation solution. Brovana is specifically indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including those with reversible obstructive airway disease. The move serves to enhance Lupin Ltd.'s presence in the field of respiratory therapy. Sunovion Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the treatment of reversible airway diseases.

Major companies operating in the reversible airway diseases treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Grifols SA, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher & Paykel Healthcare Corporation Limited.

North America was the largest region in the reversible airway diseases treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reversible airway disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the reversible airway disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Reversible Airway Diseases Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on reversible airway diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for reversible airway diseases treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The reversible airway diseases treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment : Chest X Ray; Computed Tomography (CT) Scan; Lung Therapies; Surgery Transplant; Medications
  • 2) By Diseases: Asthma; Chronic Bronchitis; Emphysema; Cystic Fibrosis; Bronchiolitis; Other Diseases
  • 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
  • 2) By Computed Tomography (CT) Scan: High-Resolution CT Scan; Spiral CT Scan
  • 3) By Lung Therapies: Inhalation Therapy; Pulmonary Rehabilitation; Oxygen Therapy
  • 4) By Surgery Transplant: Lung Transplant; Bronchoscopic Procedures; Other Surgical Interventions
  • 5) By Medications: Bronchodilators; Corticosteroids; Anticholinergics; Other Medications
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Reversible Airway Diseases Treatment Market Characteristics

3. Reversible Airway Diseases Treatment Market Trends And Strategies

4. Reversible Airway Diseases Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Reversible Airway Diseases Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Reversible Airway Diseases Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Reversible Airway Diseases Treatment Market Growth Rate Analysis
  • 5.4. Global Reversible Airway Diseases Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Reversible Airway Diseases Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Reversible Airway Diseases Treatment Total Addressable Market (TAM)

6. Reversible Airway Diseases Treatment Market Segmentation

  • 6.1. Global Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chest X Ray
  • Computed Tomography (CT) Scan
  • Lung Therapies
  • Surgery Transplant
  • Medications
  • 6.2. Global Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Asthma
  • Chronic Bronchitis
  • Emphysema
  • Cystic Fibrosis
  • Bronchiolitis
  • Other Diseases
  • 6.3. Global Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users
  • 6.4. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Chest X-Ray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Standard Chest X-Ray
  • Digital Chest X-Ray
  • 6.5. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Computed Tomography (CT) Scan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • High-Resolution CT Scan
  • Spiral CT Scan
  • 6.6. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Lung Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Inhalation Therapy
  • Pulmonary Rehabilitation
  • Oxygen Therapy
  • 6.7. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of By Surgery Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Transplant
  • Bronchoscopic Procedures
  • Other Surgical Interventions
  • 6.8. Global Reversible Airway Diseases Treatment Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bronchodilators
  • Corticosteroids
  • Anticholinergics
  • Other Medications

7. Reversible Airway Diseases Treatment Market Regional And Country Analysis

  • 7.1. Global Reversible Airway Diseases Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Reversible Airway Diseases Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Reversible Airway Diseases Treatment Market

  • 8.1. Asia-Pacific Reversible Airway Diseases Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Reversible Airway Diseases Treatment Market

  • 9.1. China Reversible Airway Diseases Treatment Market Overview
  • 9.2. China Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Reversible Airway Diseases Treatment Market

  • 10.1. India Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Reversible Airway Diseases Treatment Market

  • 11.1. Japan Reversible Airway Diseases Treatment Market Overview
  • 11.2. Japan Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Reversible Airway Diseases Treatment Market

  • 12.1. Australia Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Reversible Airway Diseases Treatment Market

  • 13.1. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Reversible Airway Diseases Treatment Market

  • 14.1. South Korea Reversible Airway Diseases Treatment Market Overview
  • 14.2. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Reversible Airway Diseases Treatment Market

  • 15.1. Western Europe Reversible Airway Diseases Treatment Market Overview
  • 15.2. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Reversible Airway Diseases Treatment Market

  • 16.1. UK Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Reversible Airway Diseases Treatment Market

  • 17.1. Germany Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Reversible Airway Diseases Treatment Market

  • 18.1. France Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Reversible Airway Diseases Treatment Market

  • 19.1. Italy Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Reversible Airway Diseases Treatment Market

  • 20.1. Spain Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Reversible Airway Diseases Treatment Market

  • 21.1. Eastern Europe Reversible Airway Diseases Treatment Market Overview
  • 21.2. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Reversible Airway Diseases Treatment Market

  • 22.1. Russia Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Reversible Airway Diseases Treatment Market

  • 23.1. North America Reversible Airway Diseases Treatment Market Overview
  • 23.2. North America Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Reversible Airway Diseases Treatment Market

  • 24.1. USA Reversible Airway Diseases Treatment Market Overview
  • 24.2. USA Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Reversible Airway Diseases Treatment Market

  • 25.1. Canada Reversible Airway Diseases Treatment Market Overview
  • 25.2. Canada Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Reversible Airway Diseases Treatment Market

  • 26.1. South America Reversible Airway Diseases Treatment Market Overview
  • 26.2. South America Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Reversible Airway Diseases Treatment Market

  • 27.1. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Reversible Airway Diseases Treatment Market

  • 28.1. Middle East Reversible Airway Diseases Treatment Market Overview
  • 28.2. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Reversible Airway Diseases Treatment Market

  • 29.1. Africa Reversible Airway Diseases Treatment Market Overview
  • 29.2. Africa Reversible Airway Diseases Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Reversible Airway Diseases Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Reversible Airway Diseases Treatment Market Competitive Landscape
  • 30.2. Reversible Airway Diseases Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Reversible Airway Diseases Treatment Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. GlaxoSmithKline Plc
  • 31.3. Medtronic plc
  • 31.4. Eli Lilly and Company
  • 31.5. Gilead Sciences Inc.
  • 31.6. Amgen Inc.
  • 31.7. Boehringer Ingelheim International GmbH
  • 31.8. Viatris Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Grifols SA
  • 31.11. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Dragerwerk AG & Co. KGaA
  • 31.14. Dr. Reddy's Laboratories Ltd.
  • 31.15. Cipla Limited

32. Global Reversible Airway Diseases Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Reversible Airway Diseases Treatment Market

34. Recent Developments In The Reversible Airway Diseases Treatment Market

35. Reversible Airway Diseases Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Reversible Airway Diseases Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Reversible Airway Diseases Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Reversible Airway Diseases Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer